Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β(3)‐adrenoceptor activation and α(1)‐adrenoceptor blockade

LINKED ARTICLE: This article is commented on by Michel, M. C., pp. 429‐430 of this issue. To view this commentary visit http://dx.doi.org/10.1111/bph.13379. BACKGROUND AND PURPOSE: Mirabegron is the first β(3)‐adrenoceptor agonist approved for treatment of overactive bladder syndrome. This study aim...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Pharmacol
Auteurs principaux: Alexandre, E C, Kiguti, L R, Calmasini, F B, Silva, F H, da Silva, K P, Ferreira, R, Ribeiro, C A, Mónica, F Z, Pupo, A S, Antunes, E
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2016
Sujets:
Research Papers
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4728418/
https://ncbi.nlm.nih.gov/pubmed/26493129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13367
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires